Sipagladenant clinical trials
Also written KW-6356.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses sipagladenant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KW-6356
- 7
Studies by the year they started
8 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses sipagladenant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356CompletedPhase 1Kyowa Kirin, Inc.NCT04147910Written as KW-6356How we know
- Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major MetaboliteCompletedPhase 1Kyowa Kirin, Inc.NCT04190654Written as KW-6356How we know
- A Through QT/QTc Study of KW-6356CompletedPhase 1Kyowa Kirin Co., Ltd.NCT04342273Written as KW-6356How we know
- A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsCompletedPhase 2Kyowa Kirin Co., Ltd.NCT03703570Written as KW-6356How we know
- A Drug Interaction Study of KW-6356 and Clarithromycin or RifampicinCompletedPhase 1Kyowa Kirin Co., Ltd.NCT04070495Written as KW-6356How we know
- A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinCompletedPhase 1Kyowa Kirin Co., Ltd.NCT03970798Written as KW-6356How we know
- A Study of Single and Multiple Doses of KW-6356 in Healthy SubjectsCompletedPhase 1Kyowa Kirin Co., Ltd.NCT03830528Written as KW-6356 Low DoseHow we know
- A Study of KW-6356 in Subjects With Early Parkinson's DiseaseCompletedPhase 2Kyowa Kirin Co., Ltd.NCT02939391Written as KW-6356How we know
Codes
What other systems call sipagladenant · ClinicalTrials.gg INT016557
- UNII (FDA) FF2012ZV92SIPAGLADENANTOne source FDA
- NCI Thesaurus C190445SipagladenantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FF2012ZV92 | SIPAGLADENANT | One source FDA |
| NCI Thesaurus | C190445 | Sipagladenant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.